Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-up
dc.contributor.author | Abreu, D. R. | |
dc.contributor.author | Reck, M. | |
dc.contributor.author | Sendur, N. | |
dc.contributor.author | Park, K. | |
dc.contributor.author | Lee, D. H. | |
dc.contributor.author | Cicin, I. | |
dc.contributor.author | Yumuk, P. F. | |
dc.contributor.author | Orlandi, F. J. | |
dc.contributor.author | Leal, T. A. | |
dc.contributor.author | Soparattanapaisarn, N. | |
dc.contributor.author | Langleben, A. | |
dc.contributor.author | Califano, Raffaele | |
dc.contributor.author | Medgyasszay, B. | |
dc.contributor.author | Hsia, T. C. | |
dc.contributor.author | Otterson, G. A. | |
dc.contributor.author | Woods, T. | |
dc.contributor.author | Jensen, E. | |
dc.contributor.author | Samkari, A. | |
dc.contributor.author | Boyer, M. | |
dc.date.accessioned | 2022-04-28T13:57:38Z | |
dc.date.available | 2022-04-28T13:57:38Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Abreu DR, Reck M, Sendur N, Park K, Lee DH, Cicin I, et al. Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-up. Annals of Oncology. 2022;33:S30-S1. | en |
dc.identifier.doi | 10.1016/j.annonc.2022.02.015 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625144 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.annonc.2022.02.015 | en |
dc.title | Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-up | en |
dc.type | Meetings and Proceedings | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2022-06-28T09:43:18Z |